Search clinical trials for: EGFR-mutation

Total 126 results

Bayer

Recruiting

A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (WUKONG-32)

Non-Small Cell Lung Cancer

China
Bayer

Recruiting

A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
Bayer

Recruiting

A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United Kingdom
Instituto Nacional de Cancerologia de Mexico

Recruiting

Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.

Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

Mexico
National University Hospital, Singapore

Recruiting

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

NSCLC

Singapore
Qianfoshan Hospital

Recruiting

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Advanced Non-small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

Non-small Cell Lung Cancer

China
Peking University People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

EGFR Positive Non-small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer
Instituto Nacional de Cancerologia de Mexico

Recruiting

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC

Non-Small Cell Lung Cancer With EGFR Mutation

Mexico
Taiho Oncology, Inc.

Recruiting

A Study of TAS3351 in NSCLC Patients With EGFRmt (TAS3351)

Non-Small Cell Lung Cancer

United States, France, Italy, Korea, Republic of, Japan, Spain, Germany, Netherlands, United Kingdom
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Non Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
Guangdong Association of Clinical Trials

Recruiting

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

MRD

China
Jun Liu

Recruiting

A Single-arm Exploratory Study of Neoadjuvant Therapy

Lung Adenocarcinoma

China
Nalo Therapeutics Inc.

Recruiting

A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer

EGFR Mutation-Related Tumors

Korea, Republic of, United States, Taiwan
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Not yet recruiting

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | EGFR Mutation-Related Tumors

United States, China
Konkuk University Medical Center
Yuhan Corporation

Recruiting

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

Non Small Cell Lung Cancer

Korea, Republic of
Peking Union Medical College

Recruiting

Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（iFORCE）

NSCLC | Brain Metastases | Furmonertinib | EGFR-mutation

China
Amsterdam UMC, location VUmc

Recruiting

Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors (COMBINATION)

Non-Small Cell Lung Cancer

Netherlands
Black Diamond Therapeutics, Inc.

Recruiting

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Non-Small Cell Lung Cancer | NSCLC | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | EGF-R Positive Non-Small Cell Lung Cancer | Advanced Lung Carcinoma | EGFR-TKI Resistant Mutation | Advanced Non-Small Cell Squamous Lung Cancer | Epidermal Growth Factor Receptor C797S | Epidermal...

United States
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC (NEOTIDE)

Non-small Cell Lung Cancer | EGFR Activating Mutation

China
Tata Memorial Hospital

Recruiting

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Asymptomatic Brain Metastases | Driver Mutation Positive Non-small Cell Lung Cancer

India
Teligene US

Recruiting

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Tongji University

Recruiting

Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma (ATHEM)

NSCLC | EGF-R Positive Non-Small Cell Lung Cancer

China
Qingdao Central Hospital

Recruiting

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Bayer

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Hong Kong, United States, Taiwan, Spain, Belgium, China, Japan, France, Korea, Republic of, Singapore, Poland, Israel, Italy, Netherlands, Portugal, Brazil
Forward Pharmaceuticals Co., Ltd.
WuXi Clinical

Recruiting

A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (FWD1509)

Carcinoma, Non-Small-Cell Lung

United States
Li-kun Chen

Recruiting

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Brain Metastases

China
National University Hospital, Singapore
Boehringer Ingelheim

Recruiting

Observational Study of Afatinib 30 mg Daily

Non-Small Cell Lung Cancer | Epidermal Growth Factor Receptor Mutation

Singapore
Shanghai Chest Hospital
Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (FOCUS-A)

Non-Small-Cell Lung Cancer

China
Beijing Dongfang Biotech Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

NSCLC
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage II

China
Fundación GECP

Recruiting

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Non Small Cell Lung Cancer | EGFR Gene Mutation

Spain
Shanghai Chest Hospital

Recruiting

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Non Small Cell Lung Cancer

China
Pfizer

Recruiting

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Japan
Sun Yat-sen University
Wu Jieping Medical Foundation

Recruiting

Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Brain Metastases | EGFR Mutation

China
Trans Tasman Radiation Oncology Group

Completed

A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN)

Metastatic Non Small Cell Lung Cancer

Singapore, Australia
Bayer

Active, not recruiting

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
Bayer

Completed

A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Netherlands
Puma Biotechnology, Inc.

Terminated

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

France, United States, Spain, Belgium, United Kingdom, Serbia, Australia, Israel, Canada, Denmark, Ireland, Italy, Korea, Republic of
Novartis Pharmaceuticals

Terminated

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

Carcinoma, Non-Small-Cell Lung

Japan, Korea, Republic of, Singapore
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
Duke University

Terminated

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Non Small Cell Lung Cancer

United States
Thoraxklinik-Heidelberg gGmbH
AstraZeneca

Completed

Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC

EGFR Positive Non-small Cell Lung Cancer

Germany
ETOP IBCSG Partners Foundation
AstraZeneca

Active, not recruiting

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO)

NSCLC Stage IV | EGFR Gene Mutation

Singapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
AstraZeneca
Parexel

Completed

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib (ELIOS)

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Spain, United States, Italy, Korea, Republic of, Malaysia
Duke University

Completed

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Non Small Cell Lung Cancer

United States
Beta Pharma Shanghai

Active, not recruiting

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

NSCLC

China
Fudan University

Completed

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Non-small-cell Lung Cancer

China

Search clinical trials for: EGFR-mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations